CRISPR 抑制脓肿分枝杆菌必需肽聚糖生物合成基因及其对β-内酰胺类药物敏感性的影响。
CRISPR Inhibition of Essential Peptidoglycan Biosynthesis Genes in Mycobacterium abscessus and Its Impact on β-Lactam Susceptibility.
机构信息
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
出版信息
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0009322. doi: 10.1128/aac.00093-22. Epub 2022 Mar 21.
Abstract
We utilized a CRISPR interference (CRISPRi) assay to control the gene expressions of two predicted essential peptidoglycan biosynthesis genes, and , in Mycobacterium abscessus and to evaluate their contribution to β-lactam susceptibility. Our results showed that CRISPR inhibition of each gene led to a significant 3-log reduction in CFU in the presence of imipenem but not for cefoxitin. These results demonstrate that CRISPRi provides an experimental approach to study drug/target interactions in M. abscessus.
摘要
我们利用 CRISPR 干扰 (CRISPRi) 测定法来控制分枝杆菌中两种预测必需的肽聚糖生物合成基因和的基因表达，并评估它们对β-内酰胺类药物敏感性的贡献。我们的结果表明，CRISPR 对每个基因的抑制作用导致在亚胺培南存在时 CFU 显著减少 3 个对数，但对头孢西丁则没有。这些结果表明，CRISPRi 为研究分枝杆菌中的药物/靶标相互作用提供了一种实验方法。
相似文献
1
CRISPR Inhibition of Essential Peptidoglycan Biosynthesis Genes in Mycobacterium abscessus and Its Impact on β-Lactam Susceptibility.
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0009322. doi: 10.1128/aac.00093-22. Epub 2022 Mar 21.
2
Effect of β-lactamase production and β-lactam instability on MIC testing results for Mycobacterium abscessus.
J Antimicrob Chemother. 2017 Nov 1;72(11):3070-3078. doi: 10.1093/jac/dkx284.
3
Synergistic Interactions of Indole-2-Carboxamides and β-Lactam Antibiotics against Mycobacterium abscessus.
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02548-19.
4
"One-Two Punch": Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes.
Clin Infect Dis. 2021 Oct 20;73(8):1532-1536. doi: 10.1093/cid/ciab535.
5
activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against .
Antimicrob Agents Chemother. 2024 May 2;68(5):e0017424. doi: 10.1128/aac.00174-24. Epub 2024 Apr 1.
6
Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex .
mBio. 2019 Feb 12;10(1):e02895-18. doi: 10.1128/mBio.02895-18.
7
Select β-Lactam Combinations Exhibit Synergy against .
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02613-18. Print 2019 Apr.
8
CRISPRi-mediated characterization of novel anti-tuberculosis targets: Mycobacterial peptidoglycan modifications promote beta-lactam resistance and intracellular survival.
Front Cell Infect Microbiol. 2023 Mar 15;13:1089911. doi: 10.3389/fcimb.2023.1089911. eCollection 2023.
9
Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates.
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02623-18. Print 2019 Mar.
10
CRISPR Interference-Based Inhibition of MAB_0055c Expression Alters Drug Sensitivity in Mycobacterium abscessus.
Microbiol Spectr. 2023 Jun 15;11(3):e0063123. doi: 10.1128/spectrum.00631-23. Epub 2023 May 9.
引用本文的文献
1
Novel C5α-substituted carbapenems enhance killing via selective target binding and reduced hydrolysis by Bla.
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0017025. doi: 10.1128/aac.00170-25. Epub 2025 Jun 17.
2
Harnessing CRISPR interference to resensitize laboratory strains and clinical isolates to last resort antibiotics.
Sci Rep. 2025 Jan 2;15(1):261. doi: 10.1038/s41598-024-81989-5.
3
Durlobactam in combination with β-lactams to combat .
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0117424. doi: 10.1128/aac.01174-24. Epub 2024 Dec 23.
4
CRISPR-Cas Systems in the Fight Against Antimicrobial Resistance: Current Status, Potentials, and Future Directions.
Infect Drug Resist. 2024 Nov 26;17:5229-5245. doi: 10.2147/IDR.S494327. eCollection 2024.
5
The CRISPR-dCas9 interference system suppresses inhA gene expression in Mycobacterium smegmatis.
Sci Rep. 2024 Oct 30;14(1):26116. doi: 10.1038/s41598-024-77442-2.
6
Rapid Gene Silencing Followed by Antimicrobial Susceptibility Testing for Target Validation in Antibiotic Discovery.
Methods Mol Biol. 2024;2833:23-33. doi: 10.1007/978-1-0716-3981-8_3.
7
CRISPR Interference-Mediated Silencing of the Gene in and Its Impact on Antimicrobial Susceptibility.
Antibiotics (Basel). 2024 May 24;13(6):483. doi: 10.3390/antibiotics13060483.
8
Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against .
mBio. 2024 Jun 12;15(6):e0060924. doi: 10.1128/mbio.00609-24. Epub 2024 May 14.
9
activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against .
Antimicrob Agents Chemother. 2024 May 2;68(5):e0017424. doi: 10.1128/aac.00174-24. Epub 2024 Apr 1.
10
CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance.
ACS Infect Dis. 2023 Jul 14;9(7):1283-1302. doi: 10.1021/acsinfecdis.2c00649. Epub 2023 Jun 22.
本文引用的文献
1
Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis.
Cell. 2021 Aug 19;184(17):4579-4592.e24. doi: 10.1016/j.cell.2021.06.033. Epub 2021 Jul 22.
2
Genome-Wide Essentiality Analysis of by Saturated Transposon Mutagenesis and Deep Sequencing.
mBio. 2021 Jun 29;12(3):e0104921. doi: 10.1128/mBio.01049-21. Epub 2021 Jun 15.
3
"One-Two Punch": Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes.
Clin Infect Dis. 2021 Oct 20;73(8):1532-1536. doi: 10.1093/cid/ciab535.
4
Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus.
Nat Rev Microbiol. 2020 Jul;18(7):392-407. doi: 10.1038/s41579-020-0331-1. Epub 2020 Feb 21.
5
Structures of Penicillin-Binding Protein 3 in Complex with Five -Lactam Antibiotics Reveal Mechanism of Inactivation.
Mol Pharmacol. 2020 Apr;97(4):287-294. doi: 10.1124/mol.119.118042. Epub 2020 Feb 21.
6
Non-tuberculous mycobacterial pulmonary disease.
Eur Respir J. 2019 Jul 11;54(1). doi: 10.1183/13993003.00250-2019. Print 2019 Jul.
7
Synergistic Efficacy of β-Lactam Combinations against Pulmonary Infection in Mice.
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00614-19. Print 2019 Aug.
8
Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex .
mBio. 2019 Feb 12;10(1):e02895-18. doi: 10.1128/mBio.02895-18.
9
Select β-Lactam Combinations Exhibit Synergy against .
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02613-18. Print 2019 Apr.
10
and β-Lactams: Emerging Insights and Potential Opportunities.
Front Microbiol. 2018 Sep 25;9:2273. doi: 10.3389/fmicb.2018.02273. eCollection 2018.
Zotero 插件